EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Local oestrogen therapy and recurrence risk in women in endocrine adjuvant breast cancer therapy

Lisette Hvid Hovgaard, Julie H Tharin, Signe Borgquist, Pernille Ravn

Ugeskrift for Læger · 2025

DOI: 10.61409/v03240184 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ugeskrift for Læger, 2025. Verfasst von Lisette Hvid Hovgaard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Afdeling for Gynækologi, Fertilitet og Fødsler, Københavns Universitetshospital - Rigshospitalet. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Estrogens, Antineoplastic Agents, Hormonal. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Women treated for breast cancer often experience vulvovaginal atrophy (VVA). Vaginal oestrogen therapy (VET) can alleviate symptoms, but the impact on the risk of breast cancer recurrence is unclear. Based on a review of published studies of VET in patients with previous breast cancer, tamoxifen (TMX) users had no increase in breast cancer recurrence. In contrast, one study suggests a higher recurrence risk among aromatase inhibitor (AI) users compared to non-users. In conclusion, this review finds that VET can safely be used as VVA treatment in TMX users, whereas it should be used cautiously in AI users.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm Recurrence, LocalEstrogensAntineoplastic Agents, HormonalHumansFemaleTamoxifenAromatase InhibitorsChemotherapy, AdjuvantAdministration, IntravaginalAtrophyRisk FactorsVaginaVulvaVaginal Diseases

Substanzen

TamoxifenEstrogensAntineoplastic Agents, HormonalAromatase Inhibitors

Autor:innen und Institutionen

  • Afdeling for Gynækologi, Fertilitet og Fødsler, Københavns Universitetshospital - Rigshospitalet.
  • Graviditet og fødsel, Københavns Universitetshospital - Herlev Hospital.
  • Kræftafdelingen, Aarhus Universitetshospital.
  • Institut for Klinisk Medicin, Aarhus Universitet.
  • Gynækologisk Obstetrisk Afdeling, Odense Universitetshospital.

Zitieren

APA

Hovgaard, L. H., Tharin, J. H., Borgquist, S., & Ravn, P. (2025). Local oestrogen therapy and recurrence risk in women in endocrine adjuvant breast cancer therapy. Ugeskrift for Læger. https://doi.org/10.61409/v03240184

Vancouver

Hovgaard LH, Tharin JH, Borgquist S, Ravn P. Local oestrogen therapy and recurrence risk in women in endocrine adjuvant breast cancer therapy. Ugeskrift for Læger. 2025. doi:10.61409/v03240184

BibTeX
@article{Hovgaard2025,
  author = {Hovgaard, Lisette Hvid and Tharin, Julie H and Borgquist, Signe and Ravn, Pernille},
  title = {Local oestrogen therapy and recurrence risk in women in endocrine adjuvant breast cancer therapy},
  journal = {Ugeskrift for Læger},
  year = {2025},
  doi = {10.61409/v03240184}
}
Kostenlos starten →